211513-37-0

Basic information

• Product Name: JTT-705
• Synonyms: JTT-705;Dalcetrapib;Unii-3D050liq3h;2-Methylpropanethioic acid S-[2-[1-(2-ethylbutyl)cyclohexylcarboxamido]phenyl] ester;Dalcetrapib(JTT-705);RO4607381;JTT-705 (Dalcetrapib);Dalcetrapib(JTT-705),JTT705
• CAS NO: 211513-37-0
• Molecular Formula: C23H35NO2S
• Molecular Weight: 389.59
• Product Categories: Inhibitor;Inhibitors
• Mol File: 211513-37-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 63-63.5 °C
• Boiling Point: 528.912 °C at 760 mmHg
• Flash Point: 273.676 °C
• Appearance: /
• Density: 1.066 g/cm³
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility: insoluble in H2O; ≥12.7 mg/mL in DMSO; ≥80.2 mg/mL in EtOH
• PKA: 13.95±0.70(Predicted)
• CAS DataBase Reference: JTT-705(CAS DataBase Reference)
• NIST Chemistry Reference: JTT-705(211513-37-0)
• EPA Substance Registry System: JTT-705(211513-37-0)

Safety Data

• Hazardous Substances Data: 211513-37-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 211513-37-0 differently. You can refer to the following data:
1. Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Dalcetrapib is a drug undergoing trials for the treatment of cardiovascular disease, dyslipidemia, peripheral arterial disease (PA D).
2. Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Dalcetrapib is a drug undergoing trials for the treatment of cardiovascular disease, dyslipidemia, peripheral arterial disease (PAD).

Biological Activity

cholesteryl ester transfer protein (cetp) is a plasma protein that transfers neutral lipids among the lipoproteins. its most important action is the exchange of cholesteryl esters in high-density lipoprotein (hdl) for triglycerides in very low-density lipoprotein. thus, cetp is a potentially atherogenic protein, and its atherogenicity has been supported by many studies. dalcetrapib is a novel inhibitors of cetp.

in vitro

dalcetrapib achieved 50% inhibition of cetp activity in human plasma at a concentration of 6 μm. the mechanism of action was considered to involve the formation of a disulfide bond between the thiol form of dalcetrapib and the cysteine residue at position 13 (cys13) of cetp. [1].

in vivo

dalcetrapib achieved 95% inhibition of cetp activity in male japanese white rabbits at an oral dose of 30 mg/kg. it increased the plasma hdl cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 or 100 mg/kg once a day for 3 days to male japanese white rabbits [1].

IC 50

6 μm for cetp inhibition in human plasma

references

[1] shinkai h, maeda k, yamasaki t, okamoto h, uchida i. bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and s-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. j med chem. 2000;43(19):3566-72.[2] fayad za, mani v, woodward m, kallend d, abt m, burgess t, fuster v, ballantyne cm, stein ea, tardif jc, rudd jh, farkouh me, tawakol a. safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-plaque): a randomised

Upstream product

• 79-30-1 isobutyryl chloride 
• 211513-15-4 bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide 
• 97-72-3 2-Methylpropionic anhydride 
• 211515-46-7 1-(2-ethyl-butyl)-cyclohexanecarbonyl chloride 
• 3814-34-4 2-ethyl-1-bromobutane 
• 381209-09-2 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid 
• 211513-21-2 Dalcetrapib 
• 98-89-5 Cyclohexanecarboxylic acid 

Relevant articles and documents

New Process

The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.

NOVEL PROCESS

The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is a useful pharmaceutical active compound.

CETP activity inhibitors

The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.